コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and transformation to a treatment-refractory blast phase).
2 apse and/or malignant progression to a fatal blast phase.
3 vely detected in JAK2V617F(-) cases with MPN-blast phase.
4 phase (CP), 9 in accelerated phase, and 8 in blast phase.
5 phase (CP), 6 in accelerated phase, and 6 in blast phase.
6 relapse, and chronic myelogenous leukemia in blast phase.
7 e, they had a high rate of transformation to blast phase.
8 ary mutation in some cases of CML during the blast phase.
9 ogenous leukemia (CML) in the accelerated or blast phase.
12 s of chronic myelogenous leukemia during the blast phase and in therapy-related myelodysplasia and ac
13 onic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymph
14 8 MPN patients, as well as 71 cases with MPN-blast phase, and correlated these findings with their cl
15 on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib
16 with Ph(+) ALL, or accelerated phase (AP) or blast phase (BP) CML achieve a major cytogenetic respons
17 enous leukemia (CML) to accelerated (AP) and blast phase (BP) is because of secondary molecular event
21 , n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-
22 or mutated BCR/ABL kinase, as is typical of blast phase cells and very primitive chronic phase CML c
23 h-risk myelodysplastic syndrome (MDS), and 1 blast-phase chronic myeloid leukemia (CML).(1) Clofarabi
24 nce of resistant subclones and experience in blast-phase chronic myeloid leukemia and acute promyeloc
25 bodies in mice transplanted with chronic and blast phase CML cells resulted in therapeutic effects me
26 of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlympho
28 Of 22 patients with accelerated-phase or blast-phase CML or Ph-positive ALL, 36% had a major hema
31 ary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute
36 aemia (two with chronic-phase and three with blast-phase disease), one with chronic myelomonocytic le
38 Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes dis
39 CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and
41 ly aggressive chronic myeloid leukemia (CML)-blast phase-like disease in mice compared with less mali
42 nts with chronic myelogenous leukemia during blast phase, myelodysplastic syndrome, or acute myelogen
45 On-treatment transformation to accelerated/blast phase occurred in four patients (2%) on bosutinib
46 patients), AML in relapse (29 patients), and blast phase of chronic myeloid leukemia (CML-BP; 10 pati
49 re were fewer progressions to accelerated or blast phase on treatment, including clonal evolution, in
50 durable responses; however, most responding blast phase patients relapse despite continued therapy.
52 h BCR-ABL(-) myeloproliferative neoplasms in blast phase receiving induction chemotherapy (55%), low-
54 gene signatures of chronic, accelerated, and blast phases suggest that the progression of chronic pha
55 o hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%,
56 lower rates of transformation to accelerated/blast phase were reported compared with patients with BC
57 out treatment, most patients progress to the blast phase when additional oncogenic mutations result i
58 ndency for transformation into leukemia (MPN-blast phase), which is hypothesized to be accompanied by
59 with imatinib in chronic phase, 23 developed blast phase, which was of sudden onset (ie, occurring in
60 P was a necessary step in the progression to blast phase, with leukemic transformation being exceedin
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。